Filing Overview
This Form 6-K was filed by I-MAB, a foreign private issuer, for the month of November 2020 and dated November 10, 2020. The filing identifies I-MAB’s principal executive offices in Shanghai, China and states that the company files annual reports on Form 20-F.
The request metadata identifies the company as Novabridge Biosciences, but the filing text identifies the registrant as I-MAB. The filing includes Exhibit 99.1, described as a press release, but the press release text is not included.
Financial and Operating Metrics
The provided filing text does not provide revenue, profit, cash flow, margins, debt, liquidity, operating results, or other financial metrics.
Material Changes
The filing text does not describe material changes versus a prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
The provided text does not include management guidance, outlook, risk factors, contingencies, or unusual items. Any such information may be contained in the omitted Exhibit 99.1 press release.
Investor Verification Items
- Confirm whether I-MAB or Novabridge Biosciences is the intended company and registrant.
- Review Exhibit 99.1 for the substantive disclosure associated with this Form 6-K.
- Verify whether the omitted press release contains financial results, clinical or operational updates, guidance, risks, or material events.
- Confirm the filing date, reporting period, and Commission File Number 001-39173.